OasisLMS

Recorded: November 12, 2025
Released: January 5, 2026
Expires: January 5, 2029

With the increasing adoption of stereoelectroencephalography (SEEG) for presurgical evaluation in drug-resistant epilepsy, clinicians face challenges in consistently formulating robust preimplantation hypotheses and accurately interpreting SEEG signals. These skills are critical for precise localization of the epileptogenic zone, yet variability in practice may limit surgical success. This session will address these gaps by reviewing best practices in hypothesis generation, highlighting key principles of anatomo-electro-clinical correlation, and providing practical strategies for systematic SEEG interpretation to optimize patient outcomes

At the end of this webinar, attendees should be able to:

1. Learn how to analyze seizure semiology and build SEEG hypothesis
    
2. Evaluate interictal and ictal SEEG data to localize the epileptogenic zone
    
3. Combine pre-SEEG and SEEG findings to make informed surgical decisions

Birgit Frauscher, MD
Dr. Birgit Frauscher is a clinician scientist whose career is dedicated to improving diagnosis and prognosis of people with epilepsy by developing new methods based on advanced electroencephalography techniques to better localize the epileptic focus in order to improve epilepsy treatment outcomes and ultimately achieve the best possible quality of life. She is currently holding the position of Director of the Duke Comprehensive Epilepsy Center and is the Lincoln Financial Group Distinguished Professor of Neurology at Duke University. She holds a secondary appointment with the Department of Biomedical Engineering at the Duke Pratt School of Engineering. Dr. Frauscher’s publication record holds over 200 peer-reviewed papers dedicated to epilepsy and sleep with a H-index of 74. Her scholarly endeavors have earned her several prestigious awards, including The Canadian Excellence in Research Award (2022), the Michael Prize of the International League against Epilepsy (2019) and the Ernst Niedermeyer Prize from the Austrian Epilepsy Society (2015).


Chengyuan Wu, MD
Dr. Wu is currently a Professor of Neurosurgery and Radiology within the Division of Epilepsy and Neuromodulation Neurosurgery at the Vickie and Jack Farber Institute for Neuroscience at Thomas Jefferson Neurosurgery.  He also serves as the Clinical Director of the Jefferson Integrated Magnetic Resonance Imaging Center (JIMRIC). He completed a combined degree program at Tufts University, where he earned his Bachelor of Science in Computer Engineering and Biomedical Engineering, his Master’s degree in Biomedical Engineering, and his Medical Degree. He went on to complete his residency in neurosurgery at Thomas Jefferson University before pursing a fellowship in Stereotactic and Functional Neurosurgery.  During his fellowship, he trained under Dr. Ashwini Sharan at Thomas Jefferson University, Dr. Kim Burchiel at Oregon Health and Science University, and Dr. Marwan Hariz at the National Hospital for Neurology and Neurosurgery in London, UK. Dr. Wu’s research is focused on advanced magnetic resonance imaging (MRI) based techniques and their direct translational applications. He leads a busy surgical epilepsy practice at Jefferson Health, which performs nearly 100 surgical procedures each year.

Disclosure Policy
It is the policy of the American Epilepsy Society (AES) to ensure balance, independence, objectivity and scientific rigor. All individuals involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. Conflicts of interest will be resolved by AES prior to an educational activity being delivered to learners.

Planning Committee, Faculty, Reviewers' Disclosures of Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, the AES requires that any person who is in a position to control content of a CME activity must disclose all relevant financial relationships that they have with an ineligible company. Unless otherwise indicated (*), none of the planners or faculty of this activity have any financial relationships to disclose. All relevant financial relationships with ineligible companies have been mitigated. The following individuals contributed to this activity's content. Update for all courses this year.

Planning Committee and Faculty
Wolfgang Muhlohofer, MD (Chair)
Jaysingh Singh, MD (Vice Chair)
Ruba Al-Ramadhani, MD
Evelyn Berman, MD
Jonathan Dashkoff, MD
Proleta Datta, MD
Alyssa Ho, MD
Matthew Hoerth, MD
Scheherazade Le, MD
Jose Montes-Rivera, MD
Georgios Ntolkeras, MD
Rebecca O'Dwyer, MD
Viktoras Palys, MD
Christopher Ryan
Priyanka Sabharwal, MD
Yash Shah
Aparna Vaddiparti
Lawrence Ver Hoef
Kristine Ziemba, MD

CME Reviewer
Shaharam Izadyar, MD, FAES

American Epilepsy Society Staff Planners
Melissa Ball, CAE, PMP

Resolution of Conflicts of Interest
It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. In accordance with the ACCME Standards for Commercial Support of CME, the AES implemented the mechanisms of prospective peer review of this CME activity, to identify and resolve any conflicts. Additionally, the content of this activity is based on the best available evidence.

Accreditation
The American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

For more information regarding contact hours, please call American Epilepsy Society 312.883.3800 or education@aesnet.org.

Credit Designation
The American Epilepsy Society designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Certificate
To receive credit for your participation in this activity, please complete the evaluation survey provided at the conclusion of the activity.

Unapproved Use Disclosure
The American Epilepsy Society requires CME authors to disclose to learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Information about pharmaceutical agents/devices that is outside of U.S. Food and Drug Administration approved labeling may be contained in this activity.

Disclaimer
This CME activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the American Epilepsy Society. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label, investigational and/or experimental uses.